TrialReader

Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC

NCT03404557 — Completed, 88 participants, University Hospital, Clermont-Ferrand
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to Adherent-Invasive Escherichia Coli

RegistryNCT03404557, acronym ROMAN
StatusCompleted
Study typeObservational
Enrollment88 (Actual)
SponsorUniversity Hospital, Clermont-Ferrand (Other); collaborators: Laboratoire M2Ish
ConditionsCrohn's Disease, Ulcerative Colitis
InterventionsProteomic analysis (Other)
Datesstart 2018-01-18, primary completion 2019-01-18, completion 2019-01-18, first posted 2018-01-19, last updated 2019-02-04
Locations1 site in France

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Crohn's Disease All trials for Ulcerative Colitis All trials of Proteomic analysis

-Summary

The M2iSH laboratory showed with two previous clinical trials that Crohn's Disease (CD) macrophages present i) a defect to control Adherent-Invasive Escherichia coli (AIEC) infection related to polymorphisms associated with CD; ii) a CD - specific cytokine secretion profile after an AIEC infection and intestinal inflammation dependent; iii) a modification of the response of CD macrophages at a basal state and after the AIEC infection. These results consolidate the hypothesis of a defect specific to CD macrophages.

That's why, the primary purpose of this study is to realize a proteomic analysis of macrophages of CD patients infected or not with AIEC and to compare them to Ulcerative Colitis (UC) patients and healthy volunteers.

Expand all sections  ·  Collapse all

+Detailed description

The macrophages characterization will be realized at a basal state and in response or not to AIEC.

Investigator aimed to 1) better understand the differences between macrophages of CD patients, UC patients and healthy volunteers but also the impact of AIEC infection on these macrophages to provide key informations to detect and characterize the defect of these macrophages; 2) highlight one or several protein in CD macrophages that could represent, in a long term, a potential therapeutic target of CD.

+Arms and interventions

ArmTypeInterventionsDescription
Crohn's Disease patients groupOther: Proteomic analysis44 patients
Ulcerative Colitis patients groupOther: Proteomic analysis22 patients
Healthy volunteers groupOther: Proteomic analysis22 patients
  • Proteomic analysis (Other): Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli

+Outcome measures

Primary outcomes

  • Compare the proteomic profile of macrophages of patients with CD to patients with UC and healthy subjects in the basal state [at day 1]: Compare concentrations of different protein types in the supernatant of macrophages from patients with CD through proteomic approaches, compared with patients with UC or controls.

Secondary outcomes

  • Comparison of concentrations of different protein types in the supernatant of macrophages [at day 1]
  • presence of subgroups of patients with CD based on the proteomic profile of their macrophages. [at day 1]
  • association between these subgroups of patients with CD and biological parameters. [at day 1]
  • associations between the proteomic profiles of macrophages of patients with CD, UC or control subjects and fecal AIEC status [at day 1]
  • associations between the levels of entry, survival and multiplication of AIEC bacteria [at day 1]
  • impact of anti-TNF treatment on the proteomic profile (s) observed for macrophages of patients with CD [at day 1]
  • associations between the Proteomic profile (s) of the macrophages derived from monocytes and their AIEC status [at day 1]
  • associations between the Proteomic profile (s) of tissue macrophages and their AIEC status [at day 1]

+Eligibility

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* \- Crohn's Disease or ulcerative colitis or healthy volunteers
* Age > 18 years
* Patients benefiting from the health insurance plan
* Patients who can read and attest to understanding the information note and informed consent

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Under guardianship or curatorship
* Refusing the genetic part of the study

+Locations (1)

FacilityCityCountryStatus
CHU Clermont-FerrandClermont-FerrandFrance

+Investigators

  • Anthony BUISSON, Principal investigator, University Hospital, Clermont-Ferrand

My Notes